Tests ivonescimab with chemotherapy against bevacizumab for colorectal cancer
Compares ivonescimab plus chemotherapy with bevacizumab plus chemotherapy in adults with metastatic colorectal cancer.
Plain-language title generated from the registry record
Registry title: Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Key facts
- Where
- Berlin, Bonn, and Hamburg, GermanySee the 3 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Has a test shown that your tumour is 'MSI-high' or 'dMMR'?
Source: NCT07228832, who can take part
Where in Germany
- BerlinBerlin, GermanyTaking people
- BonnBonn, GermanyTaking people
- HamburgHamburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Summit Therapeutics
- Trial code
- NCT07228832
- Record updated
- 5 November 2026
- Original description
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)Read full original descriptionShow less
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
Inclusion: ECOG performance status score of 0 or 1; Expected life expectancy ≥ 6 months; Patients with histologically or cytologically confirmed metastatic CRC; No prior systemic therapy for metastatic CRC; At least 1 measurable noncerebral lesion.
Exclusion: Patients who have received prior immunotherapy or anti-angiogenic therapy for colorectal cancer; Active or prior history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea); Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) disease; Resectable disease; Known BRAF V600E mutant status; Current presence of significant radiographic or clinical manifestations of gastrointestinal (GI) obstruction; Ascites requiring paracentesis within last 30 days.